Categories Earnings, Health Care

BioLineRx (BLRX): Q3 2019 Earnings Snapshot

—  BiolineRX (NASDAQ: BLRX) reported third quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the year-over period.

— Net loss per share was cents per share, narrower than a loss of 6 cents per share last year, due to higher share count.

— R&D expenses rose 11% to $5.6 million, primarily due to costs associated with the BL-8040 GENESIS and COMBAT/KEYNOTE-202 clinical trials. Results expected by the end of the year.

— BLRX shares are down 75% so far this year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Key highlights from Deere & Co.’s (DE) Q4 2024 earnings results

Deere & Company (NYSE: DE) reported its fourth quarter 2024 earnings results today. Worldwide net sales and revenues decreased 28% year-over-year to $11.14 billion. Net income was $1.24 billion, or

NVDA Earnings: Nvidia Q3 profit jumps, beats estimates

NVIDIA Corporation (NASDAQ: NVDA) on Wednesday reported a sharp increase in adjusted profit and revenue for the third quarter of 2025. Earnings also topped analysts' estimates. The tech firm’s revenues

Lowe’s Companies (LOW): A few points to note about the Q3 2024 performance

Shares of Lowe’s Companies, Inc. (NYSE: LOW) rose over 1% on Wednesday. The stock has gained 8% over the past three months. The company delivered better-than-expected earnings results for the

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top